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prognostic factor for patients with nonalcoholic fatty liver
disease (NAFLD). We performed a systematic review to
quantify the prognostic value of fibrosis stage in patients
with NAFLD and the subgroup of patients with nonalcoholic
steatohepatitis (NASH) and to assess the evidence that
change in fibrosis stage is a surrogate endpoint. METHODS:
We searched the MEDLINE, Embase, Cochrane Library, and
trial registry databases through August 2018 for prospective
or retrospective cohort studies of liver-related clinical events
and outcomes in adults with NAFLD or NASH. We collected
data on mortality (all cause and liver related) and morbidity
(cirrhosis, liver cancer, and all liver-related events) by stage
of fibrosis, determined by biopsy, for patients with NAFLD or
NASH. Using fibrosis stage 0 as a reference population, we
calculated fibrosis stage-specific relative risk (RR) and 95%
confidence interval (CI) values for mortality and morbidities.
We performed fixed-effect and random-effect model meta-
analyses. Metaregression was used to examine associations
among study design (prospective vs retrospective cohort),
overall risk of bias (medium or high), and mean duration offollow-up (in years). RESULTS: Our meta-analysis included
13 studies, comprising 4428 patients with NAFLD; 2875 of
these were reported to have NASH. Compared with no
fibrosis (stage 0), unadjusted risk increased with increasing
stage of fibrosis (stage 0 vs 4): all-cause mortality RR, 3.42
(95% CI, 2.63–4.46); liver-related mortality RR, 11.13 (95%
CI, 4.15–29.84); liver transplant RR, 5.42 (95% CI, 1.05–
27.89); and liver-related events RR, 12.78 (95% CI, 6.85–
23.85). The magnitude of RR did not differ significantly after
adjustment for confounders, including age or sex in the
subgroup of NAFLD patients with NASH. Three studies
examined the effects of increasing fibrosis on quality of life
had inconsistent findings. CONCLUSIONS: In a systematic
review and meta-analysis, we found biopsy-confirmed
fibrosis to be associated with risk of mortality and liver-
related morbidity in patients with NAFLD, with and without
adjustment for confounding factors and in patients with re-
ported NASH. Further studies are needed to assess the as-
sociation between fibrosis stage and patient quality of life
and establish that change in liver fibrosis stage is a valid
endpoint for use in clinical trials.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
The stage (or extent) of liver fibrosis, confirmed by biopsy,
is believed to be a prognostic factor for risk death in
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onalcoholic fatty liver disease (NAFLD) has
people with non-alcoholic fatty liver disease (NAFLD).
NEW FINDINGS
This systematic review and meta-analysis of 4428
patients in 13 studies found that, with and without
adjustments for potential confounding factors, fibrosis
stage was associated with all-cause mortality, liver-
related mortality, and morbidity in patients with NAFLD.
LIMITATIONS
This was a systematic review of previous publications.
There was insufficient evidence to determine whether
fibrosis stage associated with health-related quality of
life or whether a change in fibrosis stage is associated
with response to treatment.
IMPACT
It is important to monitor liver fibrosis stage in patients
with NAFLD. Studies are needed to determine whether
change in fibrosis stage can be used as an endpoint for
treatment of NAFLD.
* Authors share co-first authorship.
Abbreviations used in this paper: CI, confidence interval; CLDQ, chronic
liver disease questionnaire; CRN, NASH Clinical Research Network; FDA,
US Food and Drug Administration; FLIP, fatty liver inhibition of progres-
sion; HRQoL, health-related quality of life; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis; RCT, randomized controlled
trial; RR, relative risk; SD, standard deviation; SF-36, Short-Form 36.
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https://doi.org/10.1053/j.gastro.2020.01.043Nbecome a major health problem because of its
potential to evolve into cirrhosis, with consequential risks
of death and morbidity, including hepatocellular carci-
noma and liver transplantation.1 NAFLD is defined as fatty
change (steatosis) affecting more than than 5% of hepa-
tocytes, and it has a spectrum of histologic features
ranging from steatosis without fibrosis to nonalcoholic
steatohepatitis (NASH) with varying stages of fibrosis.2
The Fatty Liver Inhibition of Progression Steatosis–
Activity–Fibrosis criteria and the NASH Clinical Research
Network (CRN) NAFLD Activity Score are the most widely
adopted semiquantitative scores used for assessing histo-
logic disease activity.3 To sustain a diagnosis of NASH,
both require histologic evidence of the presence of stea-
tosis, hepatocyte ballooning, and lobular inflammation. In
patients with NAFLD, it is widely accepted that liver
fibrosis develops as a result of liver injury secondary to
steatohepatitis. Given that disease activity in NASH may
fluctuate over time and liver biopsy may be subject to
sampling variability, some patients with NASH may be
miscategorized as not having NASH. Moreover, the fibrosis
progression rate and the proportion of individuals with
NAFLD having fibrosis progression was similar in a long-
term study with paired patient liver biopsy samples ac-
cording to whether or not they had NASH at baseline.4
Observational studies have shown biopsy-confirmed
liver fibrosis to be a major prognostic predictor of liver-
related and overall mortality in patients with NAFLD.5
Thus, liver fibrosis is deemed a putative surrogate for dis-
ease outcome, and so reduction in fibrosis is commonly used
as a primary endpoint in clinical trials of treatments for
NASH.6 Surrogate endpoints allow for the earlier assess-
ment of the benefits of treatments without waiting for
longer-term, final patient-relevant outcomes to accrue, such
as hepatocellular cancer, cirrhosis, liver failure, liver trans-
plant, or death. However, regulators such as the US Food
and Drug Administration (FDA) and European Medicines
Agency and payers typically accept surrogate endpoints only
if their validity has been proven. In addition to evidence of
their biological and pathophysiological plausibility, evidence
of validation requires demonstration of the association be-
tween the treatment effect of the surrogate (eg, a reduction in
biopsy-confirmed fibrosis stage) and a relevant clinical
outcome (eg, reduced liver-related mortality) in the setting of
a single (or multiple) randomized controlled trial (RCT).6,7
A systematic review and meta-analysis including 5
observational cohort studies (1495 patients with NAFLD)
assessed liver fibrosis as a prognostic marker of mortal-
ity.8 The researchers reported that patients with NAFLD
and fibrosis were at increased risk of overall and liver-
related mortality and that this risk was related to
advancing fibrosis stage. However, this previous study was
subject to a number of limitations: (1) a small number of
studies and a sparse number of events (a total of 56 liver-related deaths) meant the meta-analysis results were
potentially less precise and also subject to bias9,10; (2) only
the outcome of mortality was considered; (3) the compari-
son between fibrosis stage and death did not account for the
potential confounding by factors such as age, sex, and statin
usage; (4) the study did not include analyses of the impact of
liver fibrosis in the subgroup of patients with NAFLD with
NASH; and (5) the study did not consider the question of
change in liver fibrosis as a putative surrogate endpoint.
Furthermore, we are aware of the publication of additional
primary studies since the literature searches (through
November 2016) of this prior review.
The overarching aim of this study was to undertake a
systematic review and meta-analysis to assess the evidence
for stage of liver fibrosis as a predictor for mortality, liver-
related morbidity, and health-related quality of life (HRQoL)
in patients with NAFLD and the subgroup with NASH. The
specific research questions that we sought to address were
as follows. (1) What is the evidence for liver fibrosis as a
prognostic marker of mortality, morbidity, and HRQoL in
NAFLD and NASH? (2) What is the evidence for the change
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morbidity, and HRQoL in NAFLD and NASH?
Methods
This systematic review was conducted and reported in
accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement.11 The review
was registered with the PROSPERO international prospective
register of systematic reviews (CRD42019121054).
Identification of Studies and Searches
A detailed search strategy used both indexing languages
(Medical Subject Headings and EmTree) and free text terms for
NAFLD or NASH. These terms were combined with a second set
of terms (for fibrosis) and liver-related clinical events or
patient-related outcomes. A copy of the search strategy is
available (Supplementary Table 1). The following electronic
databases were searched through August 2018 by an experi-
enced information specialist (SB): MEDLINE (Ovid), Embase
(Ovid), and Cochrane Library (Wiley), as were the trial registers
ClinicalTrials.gov, the World Health Organization International
Clinical Trials Registry Platform including International Stan-
dard Randomized Controlled Trial Number and the European
Union Clinical Trials Register. The search results were com-
bined into an Endnote (Clarivate Analytics, Philadelphia, PA),
version 9, database to facilitate reference management. The
reference lists all eligible studies, and identified systematic
reviews were checked for additional studies.
Study Selection
Studies were included in this review if they met the
following criteria:
 Study design: prospective or retrospective cohort studies,
RCTs or non-RCTs.
 Population: adult (18 years) patients with biopsy-proven
NAFLD with or without the presence of NASH
 Exposure: biopsy-confirmed liver fibrosis stage
 Outcomes: all-cause and liver-related mortality, liver-
related morbidity, and HRQoL
To fully data extract and quality assess studies, we excluded
studies available only as abstracts (study investigators were
contacted to clarify the availability of full publication). We
restricted inclusion to English language papers. We excluded
studies reporting noninvasive indices of liver fibrosis (e.g.
fibrosis-4 index, NAFLD fibrosis score).
Data Extraction and Risk of Bias Assessment
The following information was extracted from the included
studies: study design, participants’ characteristics (ie, number
of patients with NAFLD and NASH and by fibrosis stage, as well
as key confounders [see below]), method of NAFLD and NASH
diagnosis and liver fibrosis assessment, final outcomes re-
ported, length of follow-up, and outcome results.
Study risk of bias was assessed with the Quality In Prog-
nosis Studies tool.12 This prognostic risk of bias tool was
adapted to suit the requirements of this review (Supplementary
Table 2).The tool has 6 domains:
1. Study participation
2. Study attrition
3. Prognostic factor measurement
4. Outcome measurement
5. Study confounding (research team clinicians [PNN, SM]
determined the key confounders: age, sex, diabetes
mellitus, hypertension, statin use, and smoking at cohort
baseline)
6. Statistical analysis and reporting
For each domain, the adequacy of reporting by a study was
assessed as yes, partly, or no. Based on domain assessments,
studies were assigned to the following overall categories of risk
of bias:
 Low risk of bias: describes studies for which all domains
are scored as yes
 Moderate risk of bias: describes studies for which 1 or
more domains are scored as partly or 1 domain is scored
as no
 High risk of bias: describes studies for which more than 1
domain is scored as no
The rating of the overall quality of the evidence from this
review was undertaken in consideration of current guidance on
the use of the Grading of
Recommendations, Assessment, Development and Evalua-
tions (GRADE)) approach applied to prognostic studies.13Statistical Analysis
Data were analyzed in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions.14 We
extracted the number of patients who experienced mortality
(all cause and liver related) and morbidity (cirrhosis, liver
cancer, and all liver-related events) by stage of fibrosis for all
patients with NAFLD. In addition, the number of events was
also extracted separately in 2 groups of patients with NAFLD:
(1) those reported to have NASH and (2) those reported not to
have NASH. Using fibrosis stage 0 as a reference population,
fibrosis stage-specific relative risk (RR) and 95% confidence
interval (CI) for mortality and morbidity outcomes were esti-
mated within the study; an RR of >1.00 indicated an increased
risk of outcome with increasing fibrosis stage.
Although this crude (or unadjusted) RR compares risk by
stage of liver fibrosis, it does not consider the potential vari-
ability in the duration of follow-up between studies and po-
tential differences in patient characteristics between each of the
fibrosis strata, which could confound the comparison. There-
fore, we also sought to identify the hazard ratios (and their
standard error) for change in fibrosis stage adjusted for
confounders.
Using fibrosis stage 0 as reference, the continuous outcome
of HRQoL was extracted as a mean and standard deviation (or
equivalent) for each fibrosis stage. Where not reported in
publications, investigators were contacted for summary
outcome data.
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dertake meta-analysis. Statistical heterogeneity between
studies was assessed using the chi-squared test of heteroge-
neity and the Cochrane I2 statistic cutoffs: ie, 0%–40%: het-
erogeneity might not be important; 30%–60%: may represent
moderate heterogeneity; 50%–90%: may represent substantial
heterogeneity; and 75%–100%: considerable heterogeneity.14
When pooling the results across studies, we used a random-
effects meta-analysis model where there was formal evidence
of statistical heterogeneity (ie, chi-squared test P value < .10
and substantial heterogeneity as defined by an I2 statistic 
50%). For outcomes with lower levels of statistical heteroge-
neity, we applied both fixed-effect and random-effect models
and reported where there was a discrepancy in model finding.
Where there was an adequate number of studies (7
studies),14 small-study effects and publication bias were
assessed with funnel plot asymmetry and the Egger test.15
Meta-regression was used to examine the association be-
tween the predefined study level variables: study design
(prospective vs retrospective cohort), overall risk of bias (me-
dium or high), and mean duration of follow-up (in years). This
regression analysis was limited to those outcomes for which
there were contributing data from 5 studies.14 If there were
suitable data (ie, RCTs reporting change in fibrosis stage and
outcomes of interest: mortality, liver-related morbidity, and
HRQoL), we planned to calculate and report 2 key indicators of
surrogate endpoint validation.16 First, we would calculate cor-
relation coefficient and the R2 for the trial-level relationship
between intervention–control differences in fibrosis and each
of the final outcomes using weighting by the inverse of the
variance (for the treatment effect on final outcomes). Second,
from the trial-based analysis, we would estimate the surrogate
threshold effect, that is, the intercept of the prediction band of
the regression line with zero effect on the final outcome.17
All data analyses were conducted using Stata, version 16.0
(Stata Corp, College Station, TX) software.
Results
Study Selection
After de-duplication, our database searches identified a
total of 6083 titles/abstracts. A further 210 study titles were
identified from trial registers. After review of all titles and full
study publications, a total of 13 studies (15 publications)
were judged tomeet the inclusion criteria for this review.3,18–
31 The study selection process is summarized in Figure 1.
Citations and reasons why studies were excluded on review
of the full publication are listed in Supplementary Table 3.
Study and Patient Characteristics
The included 13 studies recruited a total of 4428 pa-
tients with biopsy-confirmed NAFLD, and a subgroup of
2875 patients (65%) had a histologically proven diagnosis
of NASH. Trial and study characteristics are presented in
Table 1. Twelve were observational cohort studies (7
retrospective, 5 prospective), and 1 was an RCT. The median
average age across studies was 51.0 years, and 51% of
participants were men. Populations were multimorbid, with
a high prevalence of hypertension (median, 41.6%), dia-
betes mellitus (median, 47.8%), treatment with statins(median, 24.0 %), and overweight (median average body
mass index, 31.3 kg/m2). Fibrosis staging was confirmed by
liver biopsy and centrally assessed in the majority of
multicenter studies. The distribution of patients with
NAFLD by fibrosis stage was as follows: stage 0: 1040
(23%); stage 1: 1094 (25%); stage 2: 602 (14%); stage 3:
922 (21%); and stage 4: 770 (17%). Bhala et al18 and Vilar-
Gomez29 included only patients with stage 3 and 4 and were
therefore not included in the meta-analyses.
The method of NASH diagnosis was poorly described but
was judged to be adequately defined in 7 studies.20,22–
25,28,30 The 2 most common diagnostic metrics were fatty
liver inhibition of progression (FLIP) criteria or NASH CRN
(ie, presence of steatosis, ballooning, and lobular inflam-
mation). The median average duration of study follow-up
was 6.2 years, ranging from 7 months to 19.9 years.Risk of Bias Assessment
All studieswere judged to have amoderate risk of bias, with
the exception of Leung et al,24 which was deemed to be at high
risk of bias, and Vilar-Gomez,29 judged to be at low risk of bias
(see Table 2). The Quality in Prognosis Studies criteria of study
population, prognostic factor measurement, and outcome
measurementwere generallywellmet (yes orpartly); however,
there was limited consideration of criteria of attrition, con-
founding measurement, and data analysis. Only Bhala et al18
and Vilar-Gomez29 provided a sufficiently detailed descrip-
tion of loss to follow-up to assess risk of attrition, whereas the
studies of Leung et al24 and Younossi et al30 provided no in-
formation on loss to follow-up. Angulo et al5 andVilar-Gomez29
were the only studies to report all key confounders (ie, age, sex,
diabetes mellitus, hypertension, statin use, and smoking) and
adjust for them all in their data analysis. Leung et al24 failed to
report either how confounderswere taken into account or how
they were included in their data analysis.Outcomes
Fibrosis Stage Outcomes in All Patients With
Nonalcoholic Fatty Liver Disease Without Adjust-
ment for Covariates. Across the 10 studies reporting
clinical events, a total of 591 out of 3338 (17.7%) patientswith
NAFLD died over the period of follow-up, and 8 studies re-
ported 95 liver-related deaths in 2729 patients (3.5%). Seven
studies reported 52 out of 2510 (2.1%) patients NAFLD who
experienced a liver transplant. Events due to liver morbidity
were reported in 362 out of 3125 patients (11.5%) across 8
studies based on combinations of events that included liver
failure, ascites, encephalopathy, and liver cancer. Meta-
analysis showed that, compared with patients with NAFLD
and no fibrosis (stage 0), patients with fibrosis were at an
increased unadjusted RR of all-cause mortality, liver-related
mortality, liver transplant, and all-event liver morbidity, and
this risk was incremental according to fibrosis stage (see
Table 3 and Figures 2 and 3). No statistical heterogeneity (I2¼
0%)was observed for the comparison of fibrosis stages 1–4 vs
stage 0 across the 4 event outcomes.
Fibrosis-Related Event Outcomes in All Patients
With Nonalcoholic Fatty Liver Disease After
Figure 1. Summary of the
study selection process.
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of 6 studies provided hazard ratios for events comparing
mild to moderate fibrosis (stages 0–2) to advanced fibrosis
(stage 3 or 4) based on multivariable Cox regression models
that adjusted for potential key confounding covariates.21,23–
27,29 All studies adjusted their analyses for age, sex, diabetes,
and hypertension, with exception of Seko et al,27 who
adjusted for age, sex, diabetes, and statin use. No studies
included adjustment for both smoking and statin use.
Although not all studies reported data on event outcomes,
there was a clear incremental risk with advanced fibrosis
across all event outcomes, as shown by a pooled hazard
ratio of >1.0 (see Supplementary Table 4). In those studies
that provided both an adjusted and unadjusted risk ratio,
the magnitude of increased risk with advanced fibrosis
appeared to be similar, as indicated by overlapping 95% CIs.
These conclusions remained consistent when the Seko et al
study was removed from the meta-analysis.
Impact of the Presence of Nonalcoholic Steatohe-
patitis on Fibrosis-Related Event Outcomes Without
Adjustment for Covariates. Four studies reported
fibrosis-related event outcomes in a cohort of patients withNAFLD reported to either have NASH or not have
NASH.20,23–25 A low level of statistical heterogeneity (I2 ¼
0%) was seen, with the exception of liver transplant events
for stage 0 vs 4 in the subgroup without NASH, where there
was evidence of substantial heterogeneity (I2 ¼ 56%) and
was pooled using a random-effects meta-analysis (see
Table 4).
There was an increase in the unadjusted risk of events
with increasing stage of fibrosis for patients with NAFLD
irrespective of the presence of NASH. The magnitude of
increasing unadjusted risk appeared similar between pa-
tients with NAFLD with/without reported NASH, with
overlapping 95% CI of RR estimates (see Table 4 and
Supplementary Figure 1).
Fibrosis-Related Health-Related Quality of Life
Outcomes. Three studies (1089 patients with NAFLD and
718 patients with NASH) reported HRQoL using either the
generic measure, Short Form–36 (SF-36), or the liver-
specific measure, Chronic Liver Disease Questionnaire
(CLDQ). Given the heterogeneity of outcomes (generic in-
struments and liver-specific instrument but no NASH-
specific instrument), meta-analysis was not deemed
Table 1.Characteristics of the Included Studies
First author (year) and
country
Study design, time period, and
sampling frame Population diagnosis
Population
demographics Fibrosis staging
Outcomes
reported Follow-up
Angulo et al (2015)5
Australia, Denmark, Iceland,
Thailand, United
Kingdom, United States
NR centers
Retrospective cohort study
1975–2005a
Consecutive patients
619 patients with liver biopsy–
confirmed NAFLD
284 with NASH, method of
confirmation not reported
Age: median, 49 y
DM: 37.5%
White: 88%
Male: 37.5%
HTN: 30.7%
Statin use: 63%
Smoking: 8.7%
Biopsy centrally
confirmed and
reported as stage
0–4
Overall mortality,
liver transplant,
liver eventsb
Median: 12.6 y
Range: 0.3–35.1 y
Bhala et al (2011)18
Australia, Italy, United
Kingdom, United States,
Thailand
4 centers
Prospective cohort study
1984–2006a
Consecutive patients
247 patients with liver biopsy–
confirmed NAFLD with advanced
fibrosis or cirrhosis
247 with NASH, all with advanced
fibrosis or cirrhosis
Age: mean, 55 y
DM: 50.6%
White: 91.5%
Male: 39.5%
HTN: 44.1%
Statin use: 21.5%
Smoking: NR
Biopsy reviewed
independently and
reported as stage
3 and 4
Overall mortality,
liver-related
mortality,
overall vascular
events,
myocardial
infarction, total
liver events,c
varices, ascites,
encephalopathy
Mean: 7.1 y
Range: 0.5–
24.75 y
David et al (2009)19
United Kingdom (NASH CRN
Research Group)
8 centers
Cross-sectional study (based on
NAFLD prospective cohort and
PIVENS RCT)
2004–2007a
Not reported
713 patients with liver biopsy–
confirmed NAFLD
436 with NASH, method of
confirmation not reported
Age: mean, 48 y
DM: NR
White: 76.2%
Male: 37.7%
HTN: 27%
Statin use: NR
Smoking: NR
Biopsy centrally
confirmed and
reported as stage
0–4
HRQoL (SF-36) Not applicable
Hagström (2017)20,21
Sweden
2 centers
Retrospective cohort study
1971–2009d
All patients
646 patients with liver biopsy–
confirmed NAFLD
383 with NASH, defined by FLIP
algorithm
Age: mean, 48 y
DM: 14.4%
White: NR
Male: 62.2%
HTN: 30.3%
Statin use: NR
Smoking: 24.0%
Biopsy centrally
confirmed and
reported as stage
0–4
Overall mortality,
severe liver
diseasee
Mean: 19.9 y
Range: 0.4–40
Huber et al (2019)22
Germany, Spain, United
Kingdom (European
NAFLD registry)
3 centers
Prospective cohort study
Not reported
Not reported
304 patients with liver biopsy–
confirmed NAFLD
210 with NASH, defined by the
presence of steatosis, ballooning,
and lobular inflammation
Age: median, 54 y
DM: 51.3% [T2]
White: NR
Male: 53.3%
HTN: 66.8%
Statin use: NR
Smoking: NR
Biopsy centrally
confirmed and
reported as stage
0–4
HRQoL, CLDQ Up to 6 months
after biopsy
Ito et al (2019)23
Japan
2 centers
Retrospective cohort study
1999–2014e
All patients
246 patients with liver biopsy–
confirmed NAFLD
156 with NASH, defined by FLIP
criteria
Age: median, 55 y
DM: 45.1%
White: NR
Male: 52%
HTN: 41.6%
Biopsy centrally
confirmed and
reported as stage
0–4
Overall mortality,
liver cirrhosis,
liver cancer,
extrahepatic
cancer,
Median: 7.0 y
Range: 4.4–10.0
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Table 1.Continued
First author (year) and
country
Study design, time period, and
sampling frame Population diagnosis
Population
demographics Fibrosis staging
Outcomes
reported Follow-up
Statin use: NR
Smoking: NR
cardiovascular
disease
Leung et al (2017)24
Hong Kong
1 center
Prospective cohort study
2006–2015f
Consecutive patients
300g patients with liver biopsy–
confirmed NAFLD
151 with NASH, defined by FLIP
criteria
Age: mean, 51 y
DM: 55.4%
White: NR
Male: 55.7%
HTN: 55.4%
Statin use: NR
Smoking: NR
Biopsy centrally
confirmed and
reported as stage
0–4
Overall mortality,
liver-related
events,h
nonhepatic
cancer,
cardiovascular
disease
Median: 4.1 y
Range: NR
Peleg et al (2018)25
Israel
1 center
Retrospective cohort study
2005–2012f
All patients
153 patients with liver biopsy–
confirmed NAFLD
27 with NASH, defined by the
presence of steatosis, ballooning,
and lobular inflammation
Age: mean, 49.5 y
DM: 63.4% [T2]
White: NR
Male: 55.5%
HTN: 41.1%
Statin use: 53.8%
Smoking: NR
Biopsy confirmed and
reported as stage
0–4
Overall mortality,
malignancies,
liver events,i
hospital
admissions
Mean: 8.3 y
Range: 5.1–12.0 y
Sebastiani et al (2015)26
Canada
Single center
Retrospective cohort study
2004–2013j
Consecutive patients
148 patients with liver biopsy–
confirmed NAFLD,
148 with NASH, definition not
specified
Age: mean, 49.5 y
DM: 33.1%
White: NR
Male: 69.6%
HTN: 39.2%
Statin use: NR
Smoking: NR
Biopsy confirmed and
reported as stage
0–4
Clinical outcomesk Median: 5 y
Interquartile
range: 3–8 y
Seko et al (2015)27
Japan
1 center
Retrospective cohort study
1999–2013f
All patients
312 patients with liver biopsy–
confirmed NAFLD
176 with NASH, defined by Younossi
criteria29
Age: median, 59 y
DM: 35%
White: NR
Male: 51%
HTN: NR
Statin use: 40.3%
Smoking: NR
Biopsy confirmed and
reported as stage
0–4
Overall mortality,
malignancies
Median: 4.8 y
Range: 0.3–15.7 y
Vilar-Gomez (2018)28
Australia, Cuba, Hong Kong,
Spain
5 centers
Prospective cohort study
1995–2016l
Consecutive patients
458 patients with liver biopsy–
confirmed NAFLD
458 with assumed-to-be NASH by
nature of stage 3–4 fibrosis
Age: mean, 55.9 y
DM: 67%
White: 81%
Male: 48%
HTN: 61%
Statin use: 24%
Smoking: 17%
Biopsy reviewed
independently and
reported as stage
3 and 4
Overall mortality,
major clinical
eventsm
Mean: 5.5 y
Range: 2.7–8.2
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Table 1.Continued
First author (year) and
country
Study design, time period, and
sampling frame Population diagnosis
Population
demographics Fibrosis staging
Outcomes
reported Follow-up
Younossi et al (2011,
2017)29,30
United States
3 centers
Retrospective cohort study
Not reported
Not reported
210n patients with liver biopsy–
confirmed NAFLD
131 with NASH, defined by the
presence of steatosis, ballooning,
and lobular inflammation
Age: mean, 49 yo
DM: 20.5% [T2]
White: NR
Male: 37.8%
HTN: NR
Statin use: NR
Smoking: NR
Biopsy-confirmed
NAS and Brunt 0–4
fibrosis
Liver-related
mortality
Median: 12.1 y
IQR: 4.9–15.5
Younossi et al (2018)31
United States/Canada
23 centers
Randomized controlled trial
2015–2017l
Not reported
72 patients with liver biopsy–
confirmed NAFLD
72 with NASH, defined by the
presence of steatosis, ballooning,
and lobular inflammation
Age: mean, 54 y
DM: 70.8%
White: 90.3%
Male: 30.6%
HTN: 66.7%
Statin use: NR
Smoking: NR
Biopsy-confirmed
stage 2 or 3
fibrosis
Health-related
quality of life
(SF-36 and
CLDQ)
Up to 24 weeks
DM, diabetes mellitus; HTN, hypertension; PIVENS, Pioglitazone, Vitamin E or Placebo for Nonalcoholic Steatohepatitis trial; NAS, NAFLD Activity Score; NR, not reported,
T2, Type 2 diabetes mellitus.
aYear of recruitment.
bGastroesophageal varices/bleeding, ascites, portosystemic encephalopathy, spontaneous bacterial peritonitis, hepatocellular cancer, hepatopulmonary syndrome,
hepatorenal syndrome.
cLiver failure, gastroesophageal varices, ascites, encephalopathy, hepatopulmonary syndrome, hepatocellular carcinoma.
dYear of diagnosis.
eAcute and subacute liver failure, ascites, esophageal varices, hepatorenal syndrome, chronic liver failure, cirrhosis non-ulcer dyspepsia, hepatic encephalopathy, liver
failure NUD, portal hypertension, hepatocellular carcinoma.
fYear of biopsy.
gThere were 307 patients reported in the article, but data provided by research groups included only 300.
hHepatocellular carcinoma, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, variceal bleeding, hepatic encephalopathy, liver transplant.
iEsophageal varices, hepatic encephalopathy, ascites, and transjugular intrahepatic portosystemic shunting.
jYear of study visits.
kDeath, liver transplant, cirrhosis complications.
lYears of study.
mFirst event of hepatic decompensation, hepatic chronic cirrhosis, major vascular events, and non-hepatic malignancies.
nBased on number reported in Dulai et al review.8
oWeighted mean.
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Table 2.Assessment of Risk of Bias of Included Studies, Based on Quality in Prognosis Studies Tool
First author (year)
Study
population
Study
attrition
Prognostic
factor
measurement
Outcome
measurement
Confounding
assessment
and account
Data analysis
and reporting
Overall
assessmenta
Angulo et al (2015)5 Yes Partly Yes Partly Yes Yes Moderate risk of bias
Bhala et al (2011)18 Yes Yes Yes Yes Yes Partly Moderate risk of bias
David et al (2009)19 Partly No Yes Yes Partly Partly Moderate risk of bias
Hagström (2017)20,21 Yes Partly Yes Yes Partly Partly Moderate risk of bias
Huber et al (2019)22 Partly No Yes Yes Partly Partly Moderate risk of bias
Ito et al (2019)23 Yes Partly Yes Yes Partly Partly Moderate risk of bias
Leung et al (2017)24 Yes Partly Partly Yes No No High risk of bias
Peleg et al (2018)25 Yes Partly Yes Yes Partly Partly Moderate risk of bias
Sebastiani et al (2015)26 Yes Partly Yes Yes Partly Partly Moderate risk of bias
Seko et al (2015)27 No Partly Partly Partly Partly Partly Moderate risk of bias
Vilar-Gomez et al (2018)28 Yes Yes Yes Yes Yes Yes Low risk of bias
Younossi et al (2011, 2017)29,30 Partly Partly Yes Yes Partly No Moderate risk of bias
Younossi et al (2018)31 Partly Yes Yes Yes Yes No Moderate risk of bias
aLow risk of bias describes studies for which all domains are scored as yes. Moderate risk of bias describes studies for which 1
or more domains are scored as partly or 1 domain is scored as no. High risk of bias describes studies for which more than 1
domain is scored as no.
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across individual studies (see Supplementary Table 5).
The cross-sectional analysis of David et al19 used the
generic SF-36 to report that in a total of 713 patients with
NAFLD, those with stage 4 fibrosis (cirrhosis) had signifi-
cantly (P < .001) worse physical health as assessed by SF-
36 Physical Component Score compared with patients
with NAFLD and fibrosis stages 0–3 (median, 37 vs 47–50; P
< .001). This finding remained after adjustment for poten-
tial confounders (ie, age, sex, race, marital status, education,
annual household income, body mass index, type 2 dia-
betes). The study investigators reported no significant dif-
ference across fibrosis stage for SF-36 Mental Component
Score (data not reported). Those with NASH reported
significantly poorer physical health compared with those
with no NASH (median, 22.5 vs. 47.1; P < .02).
The prospective cohort of Huber et al22 found no dif-
ference in unadjusted total CLDQ score comparing a total of
304 patients with NAFLD stage 3 or 4 and stage 0–2 fibrosis
(mean [SD], 4.9 [1.2] vs 5.1 [1.3]; P ¼ .07). NASH was
associated with a significantly lower HRQoL compared with
patients with NAFL (mean [SD], 4.85 [1.3] vs 5.31 [1.1]; P <
.01).
In an RCT with 72 patients with NASH, Younossi et al31
found no difference in unadjusted baseline HRQoL between
stage 2 and 3 fibrosis in either SF-36 (Physical Component
Score: mean [SD], 45.0 [9.6] vs 43.4 [10.3]; Mental Compo-
nent Score: 51.0 [9.6] vs 50.6 [12.7]; both P > .05) or total
CLDQ score (mean [SD], 4.83 [1.10] vs 4.91 [1.25], P >
.05).30
Metaregression
Given the number of studies reporting clinical outcome
data, we were able to undertake univariate meta-regression
for RR analysis for all-cause mortality and all liver events for
patients with NAFLD. There was no evidence of adifferential effect of study-level characteristics (ie, study
design, overall risk of bias, or follow-up) on the impact of
stage of fibrosis for either of these outcomes (see
Supplementary Table 6).
Small Study Bias
We were able to assess small study bias for the relative
outcomes of all-cause mortality and all liver events in pa-
tients with NAFLD. There was no formal evidence of funnel
plot asymmetry, except for all liver events for comparison of
fibrosis stage 0 vs 2 (Egger test, P ¼ .05) (see
Supplementary Figure 2). This asymmetry appeared to be
due to an absence of small- to medium-sized studies with an
RR of <1.0.
Quality of Evidence
Based on the Grading of Recommendations, Assessment,
Development, and Evaluations (GRADE) approach,13 we
found the quality of evidence for fibrosis in NAFLD as a
prognostic predictor of all-cause mortality to be high and for
liver mortality to be moderate (see Supplementary Table 7).
The quality of evidence for liver-related mortality. liver
transplant, and HRQoL for both NAFLD and NASH were all
judged to be low due to the sparse number of events or
small number of studies. The outcome of all liver events was
also judged to be of low quality because of inconsistency in
its definition across studies. Given the smaller amount of
evidence (studies and events), evidence quality for all out-
comes for NASH was low.
Discussion
This systematic review and meta-analysis identified a
substantive and consistent body of international observa-
tional evidence that showed that stage of biopsy-confirmed
liver fibrosis is a strong predictor of future all-cause
Table 3.Meta-analysis: Pooled Unadjusted Relative Risk by Fibrosis Stage (Relative to Stage 0) for All Patients With NAFLD
Number of studies
Stage 0 vs
1 RR (95% CI),
P value n/N vs n/N,
I2 statistic
Stage 0 vs
2 RR (95% CI),
P value n/N vs n/N,
I2 statistic
Stage 0 vs
3 RR (95% CI),
P value n/N vs n/N,
I2 statistic
Stage 0 vs
4 RR (95% CI),
P value n/N vs n/N,
I2 statistic
All-cause mortality
8 1.12 (0.91–1.38)
135/843 vs 136/896, 0%
1.50 (1.20–1.86)
135/843 vs 103/425, 0%
2.13 (1.70–2.67)
135/843 vs 86/301, 0%
3.42 (2.63–4.46)
135/843 vs 61/169, 27%
Liver-related mortality
7 1.05 (0.35–3.16)
3/521 vs 7/755, 0%
2.53 (0.88–7.27)
3/521 vs 10/340, 0%
6.65 (1.99–22.25)
3/521 vs 12/248, 0%
11.13 (4.15–29.84), 0%
3/521 vs 22/151
Liver transplantation
6 0.40 (0.02–7.50)
0/466 vs 2/691, 0%
1.98 (0.24–16.10)
0/466 vs 3/314, 0%
RR not calculable
0/466 vs 0/205, 0%
5.42 (1.05–27.89)
0/466 vs 6/129, 0%
All liver events
7 1.02 (0.58–1.89)
18/787 vs 25/823, 0%
2.67 (1.58–4.51)
19/787 vs 39/399, 0%
5.24 (3.97–8.98)
19/787 vs 39/256, 0%
12.78 (6.85–23.85)
19/787 vs 52/156, 0%
NOTE. All meta-analyses were fixed effect.
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LIVERmortality and morbidity in NAFLD (with a 5–12 fold in-
crease in RR of death and liver-related events, including
liver failure, transplantation, and liver cancer). Beyond the
increased risk associated with fibrosis, the available data doFigure 2.Meta-analysis: unadjusted RR of all-cause mortalitnot provide evidence for additional differential risk between
the reported subgroups of patients with NAFLD with NAFL
or NASH. There was, however, limited and contradictory
evidence of the impact of stage of fibrosis on the HRQoL,y by fibrosis stage (vs stage 0) in all patients with NAFLD.
Figure 3.Meta-analysis: unadjusted RR of liver events by fibrosis stage (vs stage 0) in all patients with NAFLD.
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of the study participants, and lack of data from NASH-
specific HRQoL instruments, such as the CLDQ-NASH.32In the Context of Current Evidence
This study shows that both with and without adjustment
for key potential confounding variables, biopsy-confirmed
fibrosis is a key prognostic marker for all-cause and liver-
related mortality in patients with NAFLD.8 The size and
methodologic rigor of this study now provides the confi-
dence to support the conclusions of previous studies and
recommendations of clinical guidelines. With advancing
fibrosis, there is a stepwise increase in RR for liver
morbidity, liver mortality, and all-cause mortality.
Our review also extends previous findings to the subset
of patients who have reported histologic evidence of NASH,
showing that the risk of mortality and morbidity of
increasing fibrosis stage appears be similar in magnitude to
that seen for the whole cohort of patients with NAFLD,
which includes patients categorized as currently having
histologic evidence of NASH or non-NASH. This is particu-
larly important given the increasing focus of clinical trials on
interventions on the inclusion of patients with NASH and the
focus of these trials on a primary outcome that includes
biopsy-confirmed fibrosis.33–35The FDA recently published a table of surrogate end-
points that either have been already used in their develop-
ment programs for drugs that have been approved or are
surrogate endpoints that the FDA has indicated acceptance
of in their guidance or other documents.36,37 The FDA table
of surrogate endpoints currently lists an “improvement of
fibrosis with no worsening of steatohepatitis” as a surrogate
endpoint for clinical trials in NASH.36 Notably, our review
did not identify strong evidence from RCTs that have re-
ported an association between treatment-related improve-
ment of stage of fibrosis and mortality, morbidity, or HRQoL.
Therefore, currently, there appears to be no direct scientific
evidence to validate fibrosis improvement as an established
and validated surrogate endpoint of long-term outcomes.
Although surrogacy of fibrosis is biologically plausible, and
stage of fibrosis is a strong prognostic marker, making
fibrosis improvement a reasonable endpoint for granting
provisional regulatory approval, there is ultimately a need
to generate robust data to support this based on regulatory
treatment trials in this field. This is important because
regulatory bodies and payers, who are responsible for
health care reimbursement decisions and are typically more
stringent in their evidence requirements, prefer evidence
from final patient-relevant outcomes and will accept sur-
rogate endpoints only if they are based on formal evidence
of validation.5,6 The importance of the link between putative
Table 4.Stratified Meta-analysis: Pooled Unadjusted RR by Fibrosis Stage (Relative to Stage 0) for Patients With NAFLD With
Reported NASH vs Patients With NALFD With No Reported NASH (n ¼ 4 Studies)
Mortality and
clinical events
Stage 0 vs
1 RR (95% CI),
P value n/N vs
n/N, I2 statistic
Stage 0 vs
2 RR (95% CI),
P value n/N vs
n/N, I2 statistic
Stage 0 vs
3 RR (95% CI),
P value n/N vs
n/N, I2 statistic
Stage 0 s
4 RR (95% CI),
P value n/N vs n/N,
I2 statistic
All-cause mortality
NAFLD with NASH 0.91 (0.54–1.51)
13/83 vs 44/319, 0%
1.24 (0.74–2.07)
13/83 vs 47/202, 0%
1.99 (1.17–3.41)
13/83 vs 45/155, 0%
3.26 (1.78–5.98)
13/83 vs 31/90, 0%
NAFLD without NASH 1.15 (0.87–1.52)
46/279 vs 49/294, 29%
1.40 (0.85–2.28)
46/279 vs 17/71, 0%
2.60 (1.64–4.09)
46/279 vs 11/38, 0%
2.91 (1.08–7.87)
46/279 vs 8/23, 0%
Liver-related mortality
NAFLD with NASH 0.35 (0.07–1.77)
2/83 vs 3/319, 0%
0.78 (0.21–2.92)
2/83 vs 6/201, 0%
1.24 (0.31–4.93)
2/83 vs 10/155, 0%
3.74 (0.83–16.83)
2/83 vs 13/90, 0%
NAFLD without NASH 1.10 (0.40–3.04)
1/279 vs 3/291, 0%
7.31 (0.68–78.10)
1/279 vs 2/72, NA
26.0 (2.60–260.04)
1/279 vs 2/38, NA
8.17 (1.27–52.58)
1/279 vs 18/114, 0%
Liver transplantation
NAFLD with NASH RR not estimable
0/62 vs 0/281, NA
RR not estimable
0/62 vs 0/176, NA
RR not estimable
0/62 vs 0/114, NA
RR not estimable
0/62 vs 1/69, NA
NAFLD without NASH 0.47 (0.02–8.79)
0/245 vs 2/268, NA
3.50 (0.52–23.69)
0/245 vs 3/71, 0%
RR not estimable
0/245 vs 0/36, NA
15.07 (0.63–359.22)a
0/245 vs 3/23, 56%
All liver events
NAFLD with NASH 0.47 (0.17–1.29)
5/77 vs 9/281, 0%
1.21 (0.51–2.91)
5/77 vs 19/176, 0%
2.16 (0.85–4.47)
5/77 vs 17/114, 0%
6.48 (2.89–14.85)
5/77 vs 23/69, 0%
NAFLD without NASH 1.08 (0.45–2.58)
8/230 vs 11/268, 0%
2.85 (1.12–7.24)
8/230 vs 11/71, 0%
4.56 (1.64–12.60)
8/230 vs 7/36, 0%
9.80 (3.12–30.76)
8/230 vs 15/28, 0%
NA, not applicable.
aRandom-effects meta-analyses. All other meta-analyses were fixed effect.
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LIVERsurrogates to clinically meaningful outcomes is recognized
in the recent publication from an international workshop on
clinical trial endpoints.38Strengths and Limitations
We believe this to be the most contemporary, compre-
hensive, and methodologically robust assessment of the
literature to date, including 4428 patients with NAFLD and
591 all-cause deaths. In contrast, the systematic review and
meta-analysis of Dulai et al8 included 1495 patients with
NAFLD and 348 deaths. We extended the scope of this pre-
vious study to consider the potential impact of key
confounder variables, the subgroup of patients with NAFLD
with NASH, the impact on liver-related morbidity and patient
HRQoL, and the evidencebase for change in stageoffibrosis as
surrogate endpoint. Eleven out of 13 research teams of the
included studies provided additional quantitative outcome
data (not reported in their original published papers). As a
result, we were able to ensure the inclusiveness of our meta-
analysis. The comprehensiveness of data capture is sup-
ported by our finding of little or no publication bias.
However, we recognize that our review has some limi-
tations that largely reflect the nature and reporting of
included studies. First, our primary analysis (and where we
had most available data)—that is, estimation of pooled
RR—was based on a simple comparison of the risk of out-
comes in patients according to their stage of fibrosis
(fibrosis stage 0 as reference). Given the fact that thedemographic and clinical characteristics of patients (eg, age,
sex, diabetes status) for the fibrosis stage categories is likely
to be different, this crude (or unadjusted) analysis of RRs is
likely to be prone to confounding. However, our adjusted
analysis showed that the magnitude of outcome risk with
increased fibrosis stage (fibrosis stage 0–2 vs 3 or 4) was
similar when compared with the results of the simple (un-
adjusted) pooled RR approach to pooling studies using
hazard ratios and following adjustment for potential key
confounders. Second, although we sought to extend our
review to include data on NASH, included studies often did
not provide a clear definition or explanation of how NASH
was diagnosed. Differential diagnosis of NAFLD and NASH is
a well-recognized controversy of current clinical practice.39
To make our findings as robust as possible, we limited our
meta-analysis to the subgroup of studies that had a clear
definition of NASH, such as the FLIP or NASH CRN score.
However, even when selecting studies with a clear definition
of NASH, we recognize that some patients with NASH
(steatosis, ballooning, and lobular inflammation) may be
miscategorized as not having NASH because of sampling
error on the biopsy. Moreover, a liver biopsy represents
only a single point in time, and steatohepatitis may fluctu-
ating over time due to complex gene–environment in-
teractions and in response to weight loss. Furthermore, as
fibrosis progresses toward cirrhosis, some features of NASH,
such as steatosis and hepatocyte ballooning, may become
less prominent and, thus, a patient may be categorized as
not having active NASH, yet NASH was clearly the causative
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Rfactor in the liver fibrosis. Third, studies reported liver-
related morbidity based on differing combinations of liver-
related clinical events. Therefore, there is a need for
caution in the interpretation of the meta-analysis pooling of
this composite outcome across studies. Fourth, although we
sought to include a range of clinical outcomes, the wide
meta-analysis CIs for some fibrosis stage outcome compar-
isons indicate the relatively sparse number of events
available, especially liver transplantation. However, we also
found no evidence of publication bias. Finally, included
studies were of mixed methodologic quality—7 out of 13
studies were retrospective in design, and 3 were overall
judged to be at high risk of bias. Nevertheless, our metare-
gression analysis showed that our findings were insensitive
to either study design or overall study risk of bias.
Our review has identified several important areas for
future research. First, we need to better understand the
association between fibrosis stage and patient-reported
well-being. Future outcomes for NAFLD and NASH studies,
therefore, need to consistently collect patient HRQoL using
generic (such as the 5 level EuroQoL) and disease-specific
measures (such as the CLDQ-NASH32). Second, formal sci-
entific validation of fibrosis as an acceptable surrogate
endpoint is needed. Accepted statistical methods for sur-
rogate validation include demonstration of a surrogate–final
outcome association based on patient-level data from a
single RCT or from meta-analyses of multiple RCTs.16,40,41
This evidence need is being addressed through long-term
follow-up capturing hard clinical outcomes in all NASH
phase 3 trials that are currently recruiting (eg, REGEN-
ERATE, REVERSE, RESOLVE-IT, AURORA).42–45 Third, bi-
opsy is an invasive procedure that limits clinical
applicability in routine screening for NASH, and there is a
need, therefore, to investigate the suitability of other
noninvasive alternative biomarkers as prognostic markers
or validated surrogate endpoints, an issue that is currently
being explored by 2 large international multi-stakeholder
consortia in Europe (IMI2 LITMUS) and the United States
(FNIH NIMBLE).46,47
In conclusion, our study shows that with and without
adjustment of key confounders, biopsy-confirmed fibrosis is
a key prognostic marker of both mortality and liver-related
morbidity in NAFLD and the subgroups of patients with
NAFLD with and without reported NASH, with increasing
fibrosis stage being associated with a 5- to 12-fold increase
in the RR of liver-related events. Further evidence from
well-reported studies is needed to clarify the impact of
fibrosis stage on patient well-being (including NASH-specific
HRQoL instruments) and to confirm change in biopsy-
confirmed fibrosis as a valid surrogate endpoint in the
context of RCTs of treatments for NAFLD and NASH.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology atwww.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2020.01.043.References
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Supplementary Table 1.Search Strategy
Database: Ovid MEDLINE: 1946 to week 3 of October 2018
1 (NAFLD or NASH).mp. or non-alcoholic fatty liver.ti,ab.
2 non-alcoholic steatohepatitis.ti,ab.
3 Non-alcoholic Fatty Liver Disease/
4 exp Fatty Liver/
5 or/1-4
6 fibrosis.ti,ab.
7 fibrosis/
8 cirrhosis or cirrhoses.ti,ab.
9 or/6-8
10 surrogate$.ti,ab.
11 variceal bleed$.ti,ab.
12 decompensat$.ti,ab.
13 (scar$ adj2 liver$).ti,ab.
14 ascites.ti,ab.
15 outcome$.ti,ab.
16 disease progress$.ti,ab,
17 (patient adj3 outcome$) or PROM$.ti,ab
18 ((liver) adj2 (cancer or transplant$ or carcinoma$ or
failure)).ti,ab
19 death$.mp. or mortality.ti,ab
20 hepatocellular cancer.ti,ab.
21 hepatic encephalopathy.ti,ab.
22 hepatoencephalopathy.ti,ab.
23 exp liver neoplasms/
24 or/10-23
25 5 and 9
26 24 and 25
27 (pre-clinical or rat or rats or mouse or mice or animal) or
animals.ti,ab
28 26 not 27
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Supplementary Table 2.Quality In Prognosis Studies Tool
Potential bias
(highlight one)
Items considered for assessment of
potential opportunity for bias Yes response No response
Evidence for response
(include extracts from
paper to illustrate
judgements) Comments
Study Population
The study sample
represents the
population on key
characteristics
sufficient to limit
potential bias to the
observed relationship
between fibrosis stage
and all-cause mortality,
liver-related morbidity,
and HRQoL.
The source population of interest is
adequately described for key
characteristics and the study setting
supports the applicability of results.
Eligibility criteria and recruitment
are adequately described and the
inclusion/exclusion criteria applied
uniformly to all screened for eligibility.
There is adequate participation in the
study by eligible individuals and
sufficient information was given about
those who did not participate. The
baseline characteristics or participants
included is adequately described for
characteristics and representative of the
population of interest.
Adult (>18 yrs) participants with
confirmed (ultrasonography or
biopsy-proven) NASH or NAFLD
AND source of patients and their
characteristics reported including
gender, age, presence of type-2
diabetes, hypertension, statin
usage, and smoking status AND
no major exclusions AND
representative population (e.g. all
consecutive patients recruited, or
random sample of patients
selected)
Non-adults included,
patient
characteristics not
adequately
described,
unconfirmed
disease, major
exclusions involved
and recruitment
method not
reported or likely to
be unrepresentative
of patient
population.
Yes Partly No
Study Attrition
Loss to follow-up (from
sample to study
population) is not
associated with key
characteristics (i.e. the
study data represent
the sample), sufficient
to limit potential bias
Attempts to collect information on
participants who dropped out of the
study are described. Reasons for loss to
follow-up are provided. There are no
important differences between key
characteristics (e.g. ethnicity, underlying
condition, age, treatment method) and
outcomes in participants who completed
the study and those who did not.
Reasons lost to follow-up reported
with numbers AND comparison of
lost versus not lost to follow-up
with no important differences, or if
important differences found
addressed in the analysis
Attrition/ denominators
not reported/
accounted for
Yes Partly No
Prognostic factor
measurement
Liver fibrosis is adequately
measured in study
participants to
sufficiently limit bias
Clear definition of fibrosis staging given,
report that biopsy confirmed and
method/setting of assessment same
across participants, and fibrosis stages
(0 to 4) provided with number of
participants in each category reported.
Adequate proportion of the study sample
has complete data on fibrosis stage.
Appropriate methods are used if
imputation is used for missing prognostic
factor data.
Data collection is prospective AND
fibrosis biopsy confirmed AND
number of participants in each
fibrosis stage reported.
Definition of fibrosis
stage not clear or
sufficiently detailed.
Yes Partly No
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Potential bias
(highlight one)
Items considered for assessment of
potential opportunity for bias Yes response No response
Evidence for response
(include extracts from
paper to illustrate
judgements) Comments
Outcome measurement
Outcomes (mortality, liver-
related events, and
health-related quality
of life) are adequately
measured in study
participants to
sufficiently limit
potential bias
Clear definition of outcome (mortality, liver-
related events, and health-related quality
of life) measurement provided, including
duration of follow-up. Outcomes
measured prior to outcome occurring.
Number of mortality, liver-related
events and health-related quality
of life recorded AND time-frame
for outcomes reported AND data
collection is prospective
outcome and time-
frame for follow-up
not reported
Yes Partly No
Confounding
measurement and
account
Important potential
confounders are
appropriately
accounted for, limiting
potential bias with
respect to fibrosis
stage
Important confounders are accounted for in
the study design (i.e. gender, age, and
type 2 diabetes status) and analysis.
Measurement of all important
confounders is adequately valid and
reliable. The method and setting of
confounding measurement are the same
for all participants. Appropriate
imputation method is used for missing
confounder data. Appropriate
adjustment used and clearly outlined.
Interventions do not confound outcomes
(mortality, liver-related events, and
health-related quality of life).
Confounders (i.e. gender, age,
presence of type-2 diabetes,
statin usage, and smoking status)
are reported AND analysis of
impact of fibrosis stage on
outcomes adjusts for confounders
and clearly described.
Confounders (i.e.
gender, age, and
type 2 diabetes
status) not reported
and no statement of
adjustment for
confounders in data
analysis or not clear.
Yes Partly No
Analysis and reporting
The statistical analysis is
appropriate for the
design of the study,
limiting potential for
presentation of invalid
results
There is sufficient presentation of data to
assess the adequacy of the analysis. The
selected statistical method of analysis is
adequate for the design of the study (e.g.
time to event analysis for mortality and
liver related events). There is no selective
reporting of results.
Statistical model used appropriate for
the study design and type of data
AND strategy and results clearly
reported AND completeness of
reporting of results
Unclear reporting of
results,
inappropriate
statistical model,
and selective
reporting of results
Yes Partly No
1625.e9
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Supplementary Table 3.Excluded Studies
1. Dam-Larsen S, Becker U, Franzmann MB, et al. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol
2009;44:1236–1243. No fibrosis by outcome analysis
2. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-
analysis. Hepatology 2017;65:1557–1565. Systematic review
3. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years
of follow-up. Hepatology 2015;61:1547–1554. Subset of Hagström 2017.20,21
4. Golabi P, Stepanova M, Pham HT, et al. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-
alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol 2018;5(1):e000198. No association between fibrosis and mortality
5. Hagström H, Nasr P, Ekstedt M, et al. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand J Gastroenterol
2017;52:87–91. Subset of Hagström 2017.20,21
6. Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease.
Hepatol Res 2005;33:72–76. No fibrosis by outcome analysis
7. Huber Y, Labenz C, Ganter M et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. J Hepatol 2017;66(Suppl
1):S597–S598. Abstract only and noninvasive fibrosis
8. Huber Y et al. Health-related quality of life correlates with histological severity in non-alcoholic fatty liver disease. J Hepatol 2018;68(Suppl
1):S831–S832. Abstract and full paper included
9. Ito T et al. Utility and limitation of non-invasive fibrosis markers for predicting the prognosis in biopsy-proven Japanese NAFLD patients. J
Hepatol 2018;68(Suppl 1):S561. Abstract and full paper included
10. Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with
nonalcoholic fatty liver disease: a systematic review and meta-analysis of cohort study. Clin Res Hepatol Gastroenterol 2017;41:629–634.
Systematic review
11. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic
fatty liver disease in the United States. Hepatology 2013;57:1357–1365. NFD score, not liver biopsy
12. Le MH, Devaki P, Ha NB, et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the
United States. PLoS One 2017;12(3):e0173499. Noninvasive fibrosis only
13. Lee T-Y, Wu J-C, Yu S-H, et al. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic
nonalcoholic fatty liver disease. Int J Cancer 2017;141:1307–1314. No inclusion of fibrosis
14. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastro-
enterology 1999;116:1413–1419. No biopsy fibrosis outcome analysis
15. Miyake N, Tada T, Kobayashi N et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic
fatty liver disease. Hepatology 2018;68(Suppl 1):974A. Abstract and noninvasive fibrosis score—forward search no paper
16. Patel JR, Dulai PS , Younossi ZM et al. Risk of mortality by fibrosis stage in NAFLD: a systematic review and meta-analysis. Hepatology
2017;64:1095A. Abstract and systematic review
17. Renelus BD, Fengxia Yan F, Flood MC et al. Comparison of noninvasive fibrosis scores and association with mortality in adults with
moderate to severe hepatic steatosis and NAFLD. Hepatology 2015:603A. Abstract and noninvasive fibrosis only
18. Sayiner M, Stepanova M, Pham H, et al. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.
BMJ Open Gastroenterol 2016;3(1):e000106. Cross-sectional study
19. Salomone F, Micek A, Godos J. Simple scores of fibrosis and mortality in patients with NAFLD: a systematic review with meta-analysis. J
Clin Med 2018;7(8):219. Systematic review
20. Sanyal A, Harrison S, Ratziu V et al. Changes in fibrosis, but not the NAFLD activity score (NAS), are associated with disease progression
in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis. J Hepatol 2017;(Suppl):S2–S3. Abstract and no fibrosis-
outcome analysis
21. Sebastiani G, Deschenes M, Alshaalan R, et al. Prediction of 10-year clinical outcomes in NASH by non-invasive fibrosis and steatosis
tools, hepatic venous pressure gradient (HVPG) and liver histology. Hepatology 2014;(1):597A. Abstract— full paper included
22. Singh A et al. Validity of non-invasive fibrosis scores to detect advanced fibrosis in patients with type 2 diabetes with suspected non-
alcoholic fatty liver disease. Am J Gastroenterol 2017;112(Suppl 1):S491–S492. Abstract and noninvasive fibrosis
23. Stauber RE et al. Enhanced liver fibrosis (ELF) score accurately detects advanced fibrosis in nonalcoholic fatty liver disease (NAFLD). J
Hepatology 2018;68(Suppl 1):S563. Abstract—noninvasive fibrosis
24. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty
liver disease (NAFLD). Dig Dis Sci 2013;58:3017–3023. No fibrosis by outcome analysis
25. Stepanova M, Rafiq N, Makhlouf H, et al. Pathologic features of non-alcoholic steatohepatitis (NASH) as independent predictors of liver-
related mortality. J Hepatol 2011;54:S25–S44. No fibrosis by outcome analysis
26. Strasser M, Feldman A, Schranz M, et al. SAF score effectively identifies NAFLD subjects at high risk of subsequent liver related but not
cardiovascular or malignancy-associated mortality and morbidity. J Hepatol 2017;66(1 Suppl):S425–S426. No fibrosis by outcome
analysis
27. Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult
patients with non-alcoholic fatty liver disease: a meta-analysis study. Hepatol Res 2016;46:862–870. Systematic review
28. Tada T, Kumada T, Toyoda H, et al. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic
fatty liver disease. Hepatol Commun 2017;1:899–910. Noninvasive fibrosis vs nonhepatic mortality
29. Treeprasertsuk S, Björnsson E, Enders F, et al. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among
NAFLD patients. World J Gastroenterol 2013;19:1219–1229. Noninvasive fibrosis score
30. Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology 2017;66:84–95.
Noninvasive fibrosis only
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31. Wijarnpreecha K, Scribani C, Ungprasert P et al. Non-invasive fibrosis markers are independent predictors of mortality among U.S. adults
with nonalcoholic fatty liver disease. J Hepatol 2017;66(Suppl 1):S662–S663. Noninvasive fibrosis only
32. Xun Y-H, Guo J-C, Lou G-Q, et al. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese
patients with NAFLD. Clin Exper Pharmacol Physiol 2014;41:643–649. Noninvasive fibrosis only
33. Yoshihisa A, Sato Y, Yokokawa T, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC
Heart Fail 2018;5:262–270. Noninvasive fibrosis only
34. Younossi ZM et al. Non-alcoholic fatty liver disease fibrosis score (NFS) is an independent predictor of mortality in patients with sNAFLD.
Hepatology 2013;(1):511A. Noninvasive fibrosis only
35. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in
the United States from 2004 to 2009. Hepatology 2015;62:1723–1730. No fibrosis by outcome analysis
36. Younossi ZM, Stepanova M, Henry L, et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-
alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 2017;37:1209–1218. Cross-sectional study
37. Younossi ZM, Stepanova M, Younossi I, Racila A. Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in
patients with biopsy-proven nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2019;17:2093–2100. No fibrosis by outcome
analysis
Supplementary Table 4.Meta-analysis: Pooled Hazard Ratio (Adjusted) and Pooled RR (Unadjusted) by Fibrosis Stage 0–2 vs
2–4 for All Patients With NAFLD
Number of Studies
Stage 0–2 vs 3–4
Adjusted hazard ratio (95% CI),
I2 statistic
Stage 0–2 vs 3–4
Unadjusted relative risk (95% CI),
I2 statistic
All-cause mortality (n ¼ 5) 2.24 (1.48–3.39), 31% 2.25 (1.85–2.72), 35%
Liver-related mortality (n ¼4) 5.12 (2.48–10.55), 0% 6.42 (3.45–11.95), 0%
Liver transplant (n ¼ 2) 10.89 (2.01–58.99), 0% 3.40 (0.96–12.00), 0%
All liver events (n ¼ 6) 5.58 (3.70–8.40), 0% 6.31, (4.60–8.65), 0%
NOTE. All results are fixed-effect meta-analysis.
Supplementary Table 5.HRQoL by Fibrosis Stage Across Individual Studies
Study (Year) Stage 0 Stage 1 Stage 2 Stage 3 Stage 4
David (2009)19 N, median (IQR) N, median (IQR) N, median (IQR) N, median (IQR) N, median (IQR)
SF-36 PCS 167, 50 (42.5–56) 211, 50 (39–54) 138, 47 (36–54) 131, 48 (37–53) 66, 37 (31–48)
SF-36 MCS NR NR NR NR NR
Huber (2018)22 N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD)
CLDQ total 36, 4.76 (NR) 74, 5.23 (NR) 67, 5.10 (NR) 82, 4.90 (NR) N, mean (SD)
Younossi (2018)31 N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD) N, mean (SD)
SF-36 PCS — — 25, 45.0 (8.7) 47, 43.4 (10.3) —
SF-36 MCS — — 25, 51.0 (9.6) 47, 50.6 (12.7) —
CLDQ total — — 25, 4.83 (1.10) 47, 4.91 (1.25) —
MCS, Mental Component Score; NR, not reported; PCS, Physical Component Score; SD, standard deviation.
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Supplementary Table 6.Univariate Meta-regression Analysis, P Values
Study level covariate
Fibrosis stage
0
vs 1
Fibrosis stage
0
vs 2
Fibrosis stage
0
vs 3
Fibrosis stage
0
vs 4
All-cause mortality
Retrospective vs prospective study design .774 .47 .48 .20
High vs moderate risk of bias .92 0.67 .67 .46
Duration of follow up, y .36 .11 .46 .12
All-liver related events
Retrospective vs prospective study design .41 .97 .28 .47
High vs moderate risk of bias .670 .80 .73 .98
Duration of follow-up, y .61 .13 .28 .51
Supplementary Table 7.GRADE Assessment of Quality of Evidence for Liver Fibrosis as a Prognostic Marker for NAFLD
Study design Risk of bias Indirectness Imprecision Additional considerationsa Quality
All-cause mortality Observational Seriousb Not seriousc Not seriousd Large effect, no publication bias,
confounder adjusted
High
Liver-related mortality Observational Seriousb Not seriousc Seriouse Large effect, no publication bias,
confounder adjusted
Moderate
Liver transplantation Observational Seriousb Not seriousc Seriouse Large effect, no publication bias,
confounder adjusted
Low
All liver events Observational Seriousb Seriousf Not seriousd Large effect, no publication bias,
confounder adjusted
Low
HRQoL Observational Seriousb Not seriousc Seriousg Large effect, no publication bias,
confounder adjusted
Low
NOTE. From Iorio et al13: High indicates very confident that the true prognosis (probability of future events) lies close to that of
the estimate. Moderate indicates moderately confident that the true prognosis (probability of future events) is likely to be close
to the estimate, but there is a possibility that it is substantially different. Low indicates that confidence in the estimate is limited:
the true prognosis (probability of future events)
aPositive considerations can allow upgrading of GRADE rating.
bRisk of bias for individual studies judged to be moderate or high (see Table 2).
cAppropriate population and outcomes.
dSufficient number of events.
eInsufficient number of events (especially for stage 0 fibrosis).
fInconsistent definition of composite outcome of all liver events across studies.
gSmall number of studies.
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